Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer

Ameera Shah’s Metropolis Healthcare Limited, the second-largest and most esteemed pathology laboratory chain in India, announced its partnership with Roche Diagnostics India and surrounding regions to launch the self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening.

According to the company, the purpose of this test launch is to improve access to cervical cancer screening throughout India by tackling social and economic obstacles, thereby facilitating early detection for women in Tier 2, Tier 3, and Tier 4 towns.

The HPV DNA test, endorsed by the World Health Organization (WHO) as a preferred screening option for preventing cervical cancer, can aid in closing the gap. This test identifies 14 high-risk HPV types within a single tube and is a clinically validated, FDA-approved, and WHO-prequalified option. It guarantees dependable and precise diagnosis, paving the path for prompt intervention and improved results. The self-collecting HPV DNA test allows women to manage their health by facilitating the simple and comfortable collection of their own samples for testing. It tackles major obstacles like stigma, unease, and restricted access to medical services.

Surendran Chemmenkotil, chief executive officer, Metropolis Healthcare said: “Cervical cancer remains a major health challenge for Indian women, despite being preventable through early screening and vaccination. By introducing advanced screening tools like the HPV DNA test, in collaboration with Roche Diagnostics India, we aim to expand access to early detection across the country. At Metropolis, we are committed to leveraging our robust scientific expertise, extensive laboratory network, and strong partnerships with hospitals and healthcare providers to ensure widespread access to this essential test. Together, we are working toward a future where cervical cancer is no longer a threat.”